Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inhibikase Therapeutics granted non-qualified stock options to purchase 128,000 shares to two newly-hired non-executive employees under its 2026 Inducement Equity Plan. The options carry a $2.055 exercise price, equal to the closing price on the September 30, 2026 effective date, with a ten-year term and standard four-year vesting.
Key figures
- Vesting
- 25% at first anniversary, then 75% in 36 equal monthly installments
- Exercise price
- 2.055
- Options granted
- 128000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.